A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G

Recruiting

Phase 2

ADX-097A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G

Sponsor:

Akebia Therapeutics

Code:

NCT06419205

Conditions

IgA Nephropathy

Lupus Nephritis (LN)

C3 (Complement Component 3) Glomerulopathy

Eligibility Criteria

Sex: All

Age: 16+

Healthy Volunteers: Not accepted

Interventions

ADX-097

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-12. This information was provided to ClinicalTrials.gov by Akebia Therapeutics on 2026-08-04.